Assessment of two synthesized curdlan derivatives as possible antioxidants and/or modulators of human PMN cells respiratory burst

Romanian Biotechnological Letters

Volumn 15, Issue 6, 2010, Pages 5718-5728

  Cremer, L ^a   Lupu, A R ^a   Badulescu, M M ^a   Mocanu, G ^b   Mihai, D ^b   Calugaru, A ^a   Apetrei, N S ^a   Moscovici, M ^c   Szegli, G ^a  

^a CANTACUZINO INSTITUTE   (Romania)

^b PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

^c NATIONAL INSTITUTE FOR CHEMICAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Romania)

Author keywords

glucan; Curdlan; Dectin 1; Oxidative stress; Pam3Cys; PMNs; ROS; TLR2

Indexed keywords

BACTERIA (MICROORGANISMS); FUNGI;

EID: 78650784009     PISSN: 12245984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. G.C-F. CHAN, W.K. CHAN, D.M-Y. SZE, The effects of β-glucan on human immune and cancer cells, J Hematol Oncol, 2: 25-57, (2009).
2. P.S. SAUDAGAR, R.S. SINGHAL, Curdlan as support matrix for immobilization of enzyme, Carbohydr. Polym., 56(4): 483-488 (2004).
3. B.S. KIM, I.D. JUNG, J.S. KIM, J.H. LEE, Curdlan gels as protein drug delivery vehicles, Biotechnol. Lett. 22(14): 1127-1130, (2000).
4. G. BORJIHAN, G.G. ZHONG, H. BAIGUDE, H. NAKASHIMA, T. URYU, Synthesis and anti-HIV Activity of 6-amino-6-deoxy-(1→3)-β-D-curdlan sulfate, Polymers and Advanced Technologies, 14(3-5): 326-329, (2003).
5. K.J. JEON, K. KATSURAYA, T. INAZU, Y. KANEKO, T. MIMURA, T. URYU, NMR spectroscopic detection of interaction between a HIV protein sequence and a highly anti-HIV active curdlan sulfate, J. Am Chem. Soc. 122(50): 12536-12541, (2000).
6. Y. GAO, K. KATSURAYA, Y. KANEKO, T. MIMURA, H. NAKASHIMA, T. URYU, Synthesis, enzymatic hydrolysis and anti-HIV activity of AZT-spacer-curdlan sulfates, Macromolecules, 32(25): 8319-8324, (1999).
7. K. KATSURAYA, H. NAKASHIMA, N. YAMAMOTO, T. URYU, Synthesis of sulfated oligosaccharide glycosides having high anti-HIV activity and relationship between activity and chemical structure, Carbohydr. Res., 315(3-4): 234-242, (1999).
8. Y. GAO, K. KATSURAYA, Y. KANEKO, T. MIMURA, H. NAKASHIMA, T. URYU, Synthesis of azidothimidine-bound curdlan sulfate with anti-human immunodeficiency virus activity in vitro, Polym. J., 30(1): 31-36, (1998).
9. Y. GAO, A. FUKUDA, K. KATSURAYA, Y. KANEKO, T. MIMURA, H. NAKASHIMA, T. URYU, Synthesis of regioselective substituted curdlan sulfates with medium molecular weights and their specific anti-HIV-1 activities, Macromolecules, 30(11): 3224-3228 (1997).
10. K.J. JEON, K. KATSURAYA, Y. KANEKO, T. MIMURA, T. URYU, Studies on interaction mechanism of sulfated polysaccharides as an AIDS drug by NMR, Macromolecules., 30(7), 1997-2001, (1997).
11. Z. OSAWA, T. MOROTA, K. HATANAKA, T. AKAIKE, K. MATSUZAKI, H. NAKASHIMA, N. YAMAMOTO, E. SUZUKI, H. MIYANO, T. MIMURA, Y. KANEKO, Synthesis of sulfated derivatives of curdlan and their anti-HIV activity, Carbohydr. Polym., 21(4); 283-288, (1993).
12. T. URYU, N. IKUSHIMA, K. KATSURAYA, T. SHOJI, Takahashi N, Yoshida T, Kanno K, T. MURAKAMI, h. NAKASHIMA, N. YAMAMOTO, Sulfated alkyl oligosaccharides with potent inhibitory effects on human immunodeficiency virus infections, Biochem. Pharmacol., 43(11): 2385-2392, (1992).
13. T. AOKI, Y. KANEKO, M.S. STEFANSKI, T. NGUYEN, R.C.Y. TING, Curdlan sulfate and anti-HIV-1. In vitro inhibitory effects of curdlan sulfate on HIV-1 infection, AIDS Research and Human retroviruses, 7(4): 409-415, (1991).
14. Y. KANEKO, O. YOSHIDA, R. NAKAGAWA, T. YOSHIDA, M. DATE, S. OGIHARA, S. SHIOYA, Y. MATSUZAWA, N. NAGASHIMA, Y. IRIE, T. MIMURA, H. SHINKAI, N. YASUDA, K. MATSUZAKI, T. URYU, N. YAMAMOTO, Biochem., 39(4): 793-797, (1990).
15. S. ALBAN, G. FRANZ, Partial synthetic glucan sulfates as potential new antithrombotics: A Review, Biomacromol., 2(2): 354-361, (2001).
16. I. YAMAMOTO, K. TAKAYAMA, T. GONDAM, K. MATSUZAKI, K. HATANAKA, T. YOSHIDA, T. URYU, O. YOSHIDA, H. NAKASHIMA, N. YAMAMOTO, Y. KANEKO, T. MIMURA, Synthesis, structure and antiviral activity of sulfates of curdlan and its branched derivatives, BritishPolym. J., 23(3): 245-250, (1990).
17. A. CHAIDEDGUMJORN, H. TOUODA, E.R. WOO, K.B. LEE, Y.S. KIM, T. TOIDA, T. IMANARI, Effect of (1→3) - and (1→4) - linkages of fully sulfated polysaccharides on their anticoagulant activity, Carbohydr. Res., 337(10): 925-933, (2002).
18. S. ALBAN, G. FRANZ, Characterization of the anticoagulant actions of a semisynthetic curdlan Sulfate, Thrombosis Res., 99(4): 377-388, (2000).
19. Y. YANG, X.D. GAO, T. HAN, R.X. TAN, Sulfation of a polysaccharide produced by a marine filamentous fungus alters its antioxidant properties in vitro, Biochim. Biophys. Acta., 1725: 120-127, (2005).
20. L. ZHANG, M. ZHANG, Q. ZHOU, J.H. CHEN, J.F. ZENG, Solution properties of antitumor sulfated derivative of α-(1→3)-D-glucan from Ganoderma lucidum, Biosci. Biotechnol. and Biochem., 64(10): 2172-2178, (2000).
21. Y. JIN, H. ZHANG, Y. YIN, K. NISHINARI, Comparison of curdlan and its carboxymethylated derivative by means of rheology, DSC and AFM, Carbohydr. Res., 341(1): 90-99 (2006).
22. L.N. ZHANG, M. ZHANG, J.H. CHEN, F.B. ZENG, Solution properties of antitumor carboxymethylated derivatives of α-(1→3)-D-glucan from Ganoderma lucidum, Chinese J. Polym. Sci. (Engl), 19(3): 283-289, (2001).
23. K.B. LEE, J.H. BAE, J.S. KIM, Y.C. YOO, B.S. KIM, S.T. KWAK, Y.S. KIM, Anticoagulant Activity of Sulfoalkyl Derivatives of Curdlan, Arch.Pharmacol.Res., 24(2): 109-113, (2001).
24. S. DEMLEITNER, J. KRAUS, G. FRANZ, Synthesis and antitumor activity of sulfoalkyl derivatives of curdlan and lichenan, Carbohydr. Res., 226(1): 247-252, (1992).
25. C.S. BRENANN, C.M. TUDORICA, The role of carbohydrates and nonstarch polysaccharides in the regulation of postprandial glucose and insulin reponses in cereal foods, J. Nutraceut. Funct.Med. Foods., 4: 49-55, (2003).
26. G. FROST, A.A. LEEDS, C.J. DORE, S. MADERIOS, S. BRADING, S.A. DORNHURST, Glycaemic index as a determinant of serum, cholesterol concentration, Lancet. 353: 1045-1048, (1999).
27. D.J.A. JENKINS, T.M.S. WOLEVER, J. KALMUSKY, Low glycaemic index carbohydrate foods in the management of hyperlipidaemia, Am. J. Clin. Nut., 42: 604-617 (1985).
28. K.C. MAKI, M.H. DAVIDSON, K.A. INGRAM, P.E. VEITH, M. BELL, E. GUGGER, Lipid reponses to consumption of beta-glucan containing ready-to-eat cereal in children and adolescents with mildly-to moderate primary hypercholesterolemia, Nutr. Res., 23: 1527-1535, (2003).
29. M. FERENCIK, D. KOMLOVA, L. MASLER, L. BERGENDI, J. SANDULAM, J. STEFANOVIC, Modulatory effect of glucans on the functional and biochemical activities of guinea-pig macrophages, Methods Find Exp. Clin. Pharmacol. 8: 163-166, (1986).
30. J. SANDULA, E. MACHOYA, V. HRIBOVA, Immunomodulatory activity of particulate yeast β-1,3-Dglucan and water-soluble derivatives, Int. J. Biol. Macromol., 17: 323-326, (1995).
31. G.D. ROST, Y. VETVICKA, J. YAN, Y. XIA, J. VETVIKOVA, Therapeutic intervention with complement and β-glucan in cancer, Immunopharmacology, 42, 61-74, (1999).
32. N. OHNO, N. ASADA, Y. ADACHI, T. YADOMAE, Enhancement of LPS triggered TNF-α (tumor necrosis factor-α) production by (1,3)-β-glucan in mice, Biol. Pharm. Bull., 18:126-133 (1995).
33. M. BADULESCU, N.S. APETREI, A.R. LUPU, L. CREMER, G. SZEGLI, M. MOSCOVICI, G. MOCANU, D. MIHAI, A. CALUGARU, Curdlan derivatives able to enhance cytostatic drugs activity on tumor cells, Roum.Arch.Microbiol.Immunol., 68, 4, 11-16, (2009).
34. G. MOCANU, D. MIHAI, M. MOSCOVICI, L. PICTON, D. LECERF, Curdlan microspheres. Synthesis, characterization and interaction with proteins (enzymes, vaccines), Int J Biol Macromol., 44: 215-221, (2009).
35. G.D. BROWN, J. HERRE, D.L. WILLIAMS, J.A. WILLMENT, A.S.J. MARSHALL, S. GORDON, Dectin-1 mediates the biological effects of beta-glucans, J. Exp. Med., 197:1119 - 1124 (2003).
36. H.SIES, Oxidative stress: oxidants and antioxidants, Sies H. (Ed), San Diego, CA: Academic Press, pag. 15-22, (1991).
37. R.L. PRIOR, H. HOANG, L. GU, X. WU, M. BACCHIOCCA, L. HOWARD, M. HAMPSCH-WOODILL, D. HUANG, B. OU, R. JACOB, Assay for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORACFL)) of plasma and other biological and food samples, J.Agric. Food Chem., 51: 3273-3279, (2003).
38. R. GOVINDARAJAN, M. VIJAYAKUMAR, C.V. RAO, A. SHIRWAIKAR, A.K. RAWAT, S. MEHROTRA PUSHPANGADAN, Antioxidant Potential of Anogeissus latifolia, Biol Pharm Bull., 27(8):1266-9, (2004).
39. D. ROOS, M. DE BOER, Purification and cryopreservation of phagocytes from human blood, Meth.Enzymol., 132, 225, (1986).
40. R.C. ALLEN, Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis, Methods Enzymol., 133, 449, (1986).
41. C. LAROCHE, P. MICHAUD, New Development and Perspectives Applications for β-(1,3)Glucans, Recent Patents on Biotechnology. 1: 59-73, (2007).
42. R.W. EYLER, E.D. KLUG, F. DIEPHUIS, Determination of degree of substitution of sodium carboxymethylcellulose, Anal. Chem. 19(1): 24-27, (1947).
43. W. SCHONIGER, Eine microanalytische schnelbtimmung von halogen und schwefel in organische verbindungen, Mikrochim. Acta., 869-870 (1956).
44. P.R TAYLOR, S.V. TSONI, J.A. WILLMENT, K.M. DENNEHY, M. ROSAS, H. FINDON, K. HAYNES, C. STEELE, M. BOTTO, S. GORDON, G.D. BROWN, Dectin-1 is required for β-glucan recognition and control of fungal infections. Nat. Immunol. 8, 31-38, (2007).
45. M. YADAV, J.S. SCHOREY, The β-glucan receptor Dectin-1 functions together with TLR2 to mediate macrophage activation by Mycobacteria. Blood, 108, 3168-3175 (2006).
46. G. FERWERDA, F. MEYER-WENTRUP, B-J KULBERG, M.G. NETEA, G.J. ADEMA, Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell.Microbiol., 10(10), 2058-2066, (2008).
47. M. BADULESCU, A.R. LUPU, L. CREMER, A. CALUGARU, N.S. APETREI, M. MOSCOVICI, G. MOCANU, G. SZEGLI, The modulation of reactive oxygen species production from human polumorphonuclear cells by curdlan derivatives as Dectin-1 agonists/antagonists, Roum.Arch.Microbiol.Immunol., 68, 2; 5-10, (2009).